Growth Stocks Show Potential Amid Market Stagnation in 2025

Growth investors face challenges in 2025 as the S&P 500 remains flat year-to-date, impacted by President Trump’s trade policies and persistent inflation concerns. However, some companies are thriving, fueled by advances in artificial intelligence (AI), healthcare, and technology.

The gap between market leaders and underperformers is widening. While the average stock struggles, select firms with strong competitive edges are achieving remarkable triple-digit gains. This includes AI infrastructure providers and biotech firms innovating obesity treatments, highlighting continued opportunities for significant returns.

CoreWeave: Leading AI Infrastructure

CoreWeave (NASDAQ: CRWV) is establishing itself as a crucial player in the AI sector. The firm specializes in data centers designed for GPU-intensive tasks, essential for AI applications.

This year, CoreWeave’s shares have surged 185%, with Q1 2025 revenues up 420% year-over-year, reaching $981.6 million. The company’s $11.9 billion deal with OpenAI solidifies its role as a primary AI infrastructure provider. With a revenue backlog of $25.9 billion and projected 2025 revenues between $4.9 billion and $5.1 billion, its growth potential is significant.

Despite these gains, risks exist. The company recorded a $314.6 million net loss in Q1 due to high interest expenses totaling $264 million. Furthermore, capital expenditures may reach $20 billion to $23 billion in 2025, and a large portion of its revenue depends on Microsoft, which accounts for 62% of 2024 revenues. Nonetheless, CoreWeave remains a choice for those optimistic about AI adoption.

Viking Therapeutics: Biotech Potential

Viking Therapeutics (NASDAQ: VKTX) represents a contrarian investment, having seen a 33% drop in its shares this year. The biotech company is advancing treatments for metabolic and endocrine conditions, offering multiple avenues for growth.

A key upcoming event is the Phase 2 results of its oral obesity drug VK2735, expected later this year. Additionally, Viking plans to begin Phase 3 trials for an injectable formulation soon, presenting a dual opportunity in the obesity treatment market.

With approximately $852 million in cash as of Q1 2025, Viking can support its clinical programs without equity dilution. Analysts are optimistic, with a median price target of $90, suggesting over 230% upside. The recent share decline makes it an appealing entry point for investors willing to embrace clinical risks.

Navitas Semiconductor: Power Semiconductor Innovator

Navitas Semiconductor (NASDAQ: NVTS) is at the forefront of power semiconductor innovation, focusing on gallium nitride (GaN) and silicon carbide (SiC) technologies, crucial for efficient power systems in various applications, including EVs and data centers.

Year-to-date, Navitas shares have appreciated by 42.8%, even as Q1 2025 revenues fell to $14 million from $23.2 million. A significant catalyst for growth is a partnership with Nvidia to develop an 800V HVDC architecture for AI applications. This positions Navitas centrally in the AI infrastructure sector.

The company anticipates $450 million in design wins transitioning to revenue starting late 2025, with the bulk realized in 2026. As a pioneer with over 250 million GaN units shipped, Navitas is well-positioned for future growth in the semiconductor market.

Conclusion: Evaluating Investments

Before investing in companies like CoreWeave, assess the broader market context. Analysts at Motley Fool have identified the 10 best stocks currently recommended and CoreWeave is excluded from this selection, suggesting alternative high-potential investments exist.

Historically, companies like Netflix and Nvidia have yielded substantial returns. It’s crucial to remain informed of market trends and opportunities to optimize investment strategies.

The views represented are those of the author and do not necessarily reflect those of Nasdaq, Inc.

5 Stocks Our Experts Predict Could Double In the Next Year

By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.